BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
OrbiMed Adicet Bio, Inc. (ACET) | 8.8% -0.8 13D/A [SEC] |
RA Capital Management Vor Biopharma Inc. (VOR) | 19.9% 13D/A [SEC] |
RA Capital Management Vor Biopharma Inc. (VOR) | 19.9% 13D/A [SEC] |
RA Capital Management OnKure, Inc. (OKUR) | 9.9% New 13G [SEC] |
RA Capital Management Aclaris Therapeutics, Inc. (ACRS) | 6.3% New 13G [SEC] |
RA Capital Management Zai Lab Ltd (ZLAB) | 5.2% New 13G [SEC] |
Redmile Group ADC Therapeutics SA (ADCT) | 9.9% -2.8 13G/A [SEC] |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
RA Capital Management OnKure, Inc. (OKUR) | 9.9% SC 13G [SEC] |
RA Capital Management Aclaris Therapeutics, Inc. (ACRS) | 6.3% SC 13G [SEC] |
RA Capital Management Zai Lab Ltd (ZLAB) | 5.2% SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.